Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma.

Trial Profile

Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Brostallicin (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2011 EudraCT reports status as recruiting in United Kingdom and completed in Netherlands and Germany.
    • 12 Jul 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 06 Jun 2010 Results were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top